CORONA Remedies Limited
CORONA · NSE
No price history on haylaavo yet for this symbol.
- ISIN
- INE02ZQ01018
- Series
- EQ
- Listed on NSE
- 15 Dec 2025
- Face value
- ₹10
- F&O
- No
Source: NSE equity master · as of 30 Oct 2026
Price history
Arrives in Phase 1 (full-market end-of-day ingestion). Nothing here is estimated or filled in — we only show data we have.
- Daily OHLCV and delivery % for every listed company, 10+ years
- Corporate-action adjusted series
- 52-week range, returns, moving averages
Quarterly results · Standalone · latest 30 Sept 2026
filed 30 Oct 2026, 06:54 pm IST| ₹ crore | Sept 26* |
|---|---|
| Revenue | 441 |
| Other income | 2 |
| Total expenses | 363 |
| Operating margin | 21.7% |
| Finance costs | 3 |
| Depreciation | 15 |
| Profit before tax | 81 |
| Tax | 20 |
| Net profit | 60 |
| Net margin | 13.6% |
| EPS (₹) | 9.84 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison